Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27390824 | 0.76 | CTSL (0.40) | HTR6CYP17A1CYP3A4 | |
| SCHEMBL9441562 | 0.74 | CYP3A4 (0.54) | HTR6CYP17A1CYP3A4 | |
| SCHEMBL15875088 | 0.74 | MYC (0.38) | HTR6 | |
| SCHEMBL28134284 | 0.73 | HSD11B1 (0.40) | CYP3A4 | |
| SCHEMBL29598333 | 0.72 | ALDH1A1 (0.39) | HTR6CYP17A1CYP3A4 | |
| SCHEMBL170839 | 0.72 | ALDH1A1 (0.39) | HTR6CYP17A1CYP3A4 | |
| SCHEMBL30057710 | 0.72 | HTR6 (0.40) | HTR6CES1MAOA | |
| SCHEMBL21694409 | 0.72 | HTR6 (0.40) | HTR6CES1MAOA | |
| SCHEMBL26013515 | 0.69 | ALDH1A1 (0.48) | HTR6CYP3A4 | |
| SCHEMBL17293172 | 0.69 | HTR1A (0.41) | CYP17A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148937-B1 | METALLIC COMPLEX CATALYST AND POLYMERIZATION METHODS EMPLOYING SAME | BRIDGESTONE CORP (JP) | 2019-09-18 | — | — | EP | disclosed |
| US-10017595-B2 | Metallic complex catalyst and polymerization methods employing same | BRIDGESTONE CORPORATION (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017595-B2 | Metallic complex catalyst and polymerization methods employing same | BRIDGESTONE CORPORATION (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017595-B2 | Metallic complex catalyst and polymerization methods employing same | BRIDGESTONE CORPORATION (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170114171-A1 | Metallic Complex Catalyst And Polymerization Methods Employing Same | BRIDGESTONE CORPORATION (JP) | 2017-04-27 | — | — | US | disclosed |
| US-20170114171-A1 | Metallic Complex Catalyst And Polymerization Methods Employing Same | BRIDGESTONE CORPORATION (JP) | 2017-04-27 | — | — | US | disclosed |
| US-20170114171-A1 | Metallic Complex Catalyst And Polymerization Methods Employing Same | BRIDGESTONE CORPORATION (JP) | 2017-04-27 | — | — | US | disclosed |
| EP-3148937-A1 | METALLIC COMPLEX CATALYST AND POLYMERIZATION METHODS EMPLOYING SAME | Bridgestone Corporation (JP) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015183770-A1 | METALLIC COMPLEX CATALYST AND POLYMERIZATION METHODS EMPLOYING SAME | BRIDGESTONE CORPORATION (JP) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114171-A1 | Metallic Complex Catalyst And Polymerization Methods Employing Same | C5, C1S, C9 | HTR6 2820/4885CYP17A1 1524/4885CYP3A4 212/4885 |
| US-10017595-B2 | Metallic complex catalyst and polymerization methods employing same | C5, C1S, C9 | HTR6 2820/4885CYP17A1 1524/4885CYP3A4 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.